Literature DB >> 28252203

Pathological overproduction: the bad side of adenosine.

Pier Andrea Borea1, Stefania Gessi1, Stefania Merighi1, Fabrizio Vincenzi1, Katia Varani1.   

Abstract

Adenosine is an endogenous ubiquitous purine nucleoside, which is increased by hypoxia, ischaemia and tissue damage and mediates a number of physiopathological effects by interacting with four GPCRs, identified as A1 , A2A , A2B and A3 . Physiological and acutely increased adenosine is mostly associated with beneficial effects that include vasodilatation and a decrease in inflammation. In contrast, chronic overproduction of adenosine occurs in important pathological states, where long-lasting increases in the nucleoside levels are responsible for the bad side of adenosine associated with chronic inflammation, fibrosis and organ damage. In this review, we describe and critically discuss the pathological overproduction of adenosine and analyse when, where and how adenosine exerts its detrimental effects throughout the body.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28252203      PMCID: PMC6398520          DOI: 10.1111/bph.13763

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  202 in total

1.  Hypoxia and inflammation are two sides of the same coin.

Authors:  Karsten Bartels; Almut Grenz; Holger K Eltzschig
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-01       Impact factor: 11.205

2.  Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension.

Authors:  Harry Karmouty-Quintana; Kemly Philip; Luis F Acero; Ning-Yuan Chen; Tingting Weng; Jose G Molina; Fayong Luo; Jonathan Davies; Ngoc-Bao Le; Isabelle Bunge; Kelly A Volcik; Thanh-Thuy T Le; Richard A Johnston; Yang Xia; Holger K Eltzschig; Michael R Blackburn
Journal:  FASEB J       Date:  2014-10-15       Impact factor: 5.191

3.  Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

Authors:  J F Chen; K Xu; J P Petzer; R Staal; Y H Xu; M Beilstein; P K Sonsalla; K Castagnoli; N Castagnoli; M A Schwarzschild
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

Review 4.  Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.

Authors:  Peter J Barnes
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 5.  Reparative inflammation takes charge of tissue regeneration.

Authors:  Michael Karin; Hans Clevers
Journal:  Nature       Date:  2016-01-21       Impact factor: 49.962

6.  Adenosine inhibits the adhesion of anti-CD3-activated killer lymphocytes to adenocarcinoma cells through an A3 receptor.

Authors:  W M MacKenzie; D W Hoskin; J Blay
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

7.  Caffeine, cognitive failures and health in a non-working community sample.

Authors:  Andrew P Smith
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

8.  An A2B Adenosine Receptor Agonist Promotes Th17 Autoimmune Responses in Experimental Autoimmune Uveitis (EAU) via Dendritic Cell Activation.

Authors:  Mingjiazi Chen; Dongchun Liang; Aijun Zuo; Hui Shao; Henry J Kaplan; Deming Sun
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

Review 9.  Extracellular purines, purinergic receptors and tumor growth.

Authors:  F Di Virgilio; E Adinolfi
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

10.  Early synaptic deficits in the APP/PS1 mouse model of Alzheimer's disease involve neuronal adenosine A2A receptors.

Authors:  Silvia Viana da Silva; Matthias Georg Haberl; Pei Zhang; Philipp Bethge; Cristina Lemos; Nélio Gonçalves; Adam Gorlewicz; Meryl Malezieux; Francisco Q Gonçalves; Noëlle Grosjean; Christophe Blanchet; Andreas Frick; U Valentin Nägerl; Rodrigo A Cunha; Christophe Mulle
Journal:  Nat Commun       Date:  2016-06-17       Impact factor: 14.919

View more
  36 in total

Review 1.  The Role of Adenosine Receptor Activation in Attenuating Cartilaginous Inflammation.

Authors:  Jonathan M Bekisz; Christopher D Lopez; Carmen Corciulo; Aranzazu Mediero; Paulo G Coelho; Lukasz Witek; Roberto L Flores; Bruce N Cronstein
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

2.  Blood-Brain Barrier in a Haemophilus influenzae Type a In Vitro Infection: Role of Adenosine Receptors A2A and A2B.

Authors:  N Caporarello; M Olivieri; M Cristaldi; M Scalia; M A Toscano; C Genovese; A Addamo; M Salmeri; G Lupo; C D Anfuso
Journal:  Mol Neurobiol       Date:  2017-09-18       Impact factor: 5.590

Review 3.  Pathological overproduction: the bad side of adenosine.

Authors:  Pier Andrea Borea; Stefania Gessi; Stefania Merighi; Fabrizio Vincenzi; Katia Varani
Journal:  Br J Pharmacol       Date:  2017-03-31       Impact factor: 8.739

4.  A Selective Adenosine A3 Receptor Antagonist, HL3501, Has Therapeutic Potential in Preclinical Liver and Renal Fibrosis Models.

Authors:  Woo Chan Son; Byoung-Gon Moon; Yunhee Kim; Dong Min Kim
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

Review 5.  The role of adenosine A1 receptor on immune cells.

Authors:  Lingyu Zhong; Qiao Peng; Xun Zeng
Journal:  Inflamm Res       Date:  2022-09-05       Impact factor: 6.986

Review 6.  A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases.

Authors:  Stefania Merighi; Pier A Borea; Katia Varani; Fabrizio Vincenzi; Kenneth A Jacobson; Stefania Gessi
Journal:  Curr Med Chem       Date:  2022       Impact factor: 4.740

7.  Adenosine, Via A2B Receptors, Inhibits Human (P-SMC) Progenitor Smooth Muscle Cell Growth.

Authors:  Raghvendra K Dubey; Isabella Baruscotti; Ruth Stiller; Juergen Fingerle; Delbert G Gillespie; Zaichuan Mi; Brigitte Leeners; Bruno Imthurn; Marinella Rosselli; Edwin K Jackson
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

8.  A1 and A2A Receptors Modulate Spontaneous Adenosine but Not Mechanically Stimulated Adenosine in the Caudate.

Authors:  Yuanyu Chang; Ying Wang; B Jill Venton
Journal:  ACS Chem Neurosci       Date:  2020-10-07       Impact factor: 4.418

9.  Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455.

Authors:  Stefania Gessi; Serena Bencivenni; Enrica Battistello; Fabrizio Vincenzi; Vittoria Colotta; Daniela Catarzi; Flavia Varano; Stefania Merighi; Pier Andrea Borea; Katia Varani
Journal:  Front Pharmacol       Date:  2017-12-01       Impact factor: 5.810

Review 10.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.